Bone sarcoma mortality statistics

Deaths

Deaths from bone sarcoma, 2017-2019, UK.

Percentage of all deaths

Percentage bone sarcoma contributes to total cancer deaths, 2017-2019, UK

 

Age

Peak mortality rate for bone sarcoma, 2017-2019, UK

Trend over time

Change in bone sarcoma mortality rates since the early 1970s, UK

Bone sarcoma is not among the 20 most common causes of cancer death in the UK, accounting for less than 1% of all cancer deaths (2017-2019).[1-4]

In females in the UK, bone sarcoma is not among the 20 most common causes of cancer death (less than 1% of all female cancer deaths). In males in the UK, it is the 20th most common cause of cancer death (less than 1% of all male cancer deaths).

45% of bone sarcoma deaths in the UK are in females, and 55% are in males (2017-2019).

Bone sarcoma mortality rates (European age-standardised Open a glossary item (AS) rates) in the UK are significantly lower in females than in males (2017-2019).

Bone sarcoma mortality rates (European age-standardised Open a glossary item (AS) rates) for persons are significantly higher than the UK average in Scotland, and similar to the UK average in all other UK constituent countries.

For bone sarcoma, mortality differences between countries largely reflect differences in incidence.

Bone Sarcoma (C40-C41), Annual Average Number of Deaths, Crude and European Age-Standardised (AS) Mortality Rates per 100,000 Persons Population, UK, 2017-2019

  England Scotland Wales Northern Ireland UK
Female Deaths 139 19 5 6 170
Crude Rate 0.5 0.7 0.3 0.7 0.5
AS Rate 0.5 0.7 0.3 0.7 0.5
AS Rate - 95% LCL 0.4 0.5 0.2 0.4 0.4
AS Rate - 95% UCL 0.5 0.8 0.5 1.0 0.5
Male Deaths 171 23 10 2 206
Crude Rate 0.6 0.9 0.6 0.2 0.6
AS Rate 0.7 0.9 0.6 0.2 0.7
AS Rate - 95% LCL 0.6 0.7 0.4 0.0 0.6
AS Rate - 95% UCL 0.7 1.1 0.8 0.4 0.7
Persons Deaths 311 42 15 8 376
Crude Rate 0.6 0.8 0.5 0.4 0.6
AS Rate 0.6 0.8 0.5 0.5 0.6
AS Rate - 95% LCL 0.5 0.7 0.3 0.3 0.5
AS Rate - 95% UCL 0.6 0.9 0.6 0.7 0.6

95% LCL and 95% UCL are the 95% lower and upper confidence limits around the AS Rate Open a glossary item

References

  1. England and Wales data were accessed from Nomis mortality statistics by underlying cause, sex and age, November 2021: Nomis mortality statistics by underlying cause, sex and age.
  2. Scotland data were provided by ISD Scotland on request, November 2021. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp(link is external).
  3. Northern Ireland data were provided by the Northern Ireland Cancer Registry on request, February 2022. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  4. Population data were published by the Office for National statistics, accessed July 2020. The data can be found here: Population estimates for the UK, England and Wales, Scotland and Northern Ireland, provisional: mid-2019.

See also

Data is for UK, 2017-2019, C40-C41.

Last reviewed:

Bone sarcoma mortality is strongly related to age, with the highest mortality rates being in older people. In the UK in 2017-2019, on average each year around a third of deaths (34%) were in people aged 75 and over.[1-4] This is a much lower proportion of deaths in older age groups compared with most cancers.

Age-specific mortality rates rise steadily from birth to around age 15-19 and drop until around age 40-44, then rise steadily again until around age 75-79 when the rise becomes steeper. The highest rates are in the 90+ age group for both females and males. Mortality rates are similar between females and males in most age groups.

Bone Sarcoma (C40-C41), Average Number of Deaths per Year and Age-Specific Mortality Rates per 100,000 Persons Population, UK, 2017-2019

References

  1. England and Wales data were accessed from Nomis mortality statistics by underlying cause, sex and age, November 2021: Nomis mortality statistics by underlying cause, sex and age.
  2. Scotland data were provided by ISD Scotland on request, November 2021. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp(link is external).
  3. Northern Ireland data were provided by the Northern Ireland Cancer Registry on request, February 2022. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  4. Population data were published by the Office for National statistics, accessed July 2020. The data can be found here: Population estimates for the UK, England and Wales, Scotland and Northern Ireland, provisional: mid-2019.

About this data

Data is for UK, 2017-2019, ICD-10 C40-C41.

Last reviewed:

Bone sarcoma European age-standardised Open a glossary item mortality rates for females and males combined decreased by 14% in the UK between 1979-1981 and 2017-2019.[1-4] The change varied markedly between the sexes.

For females, bone sarcoma AS mortality rates in the UK remained stable between 1979-1981 and 2017-2019. For males, bone sarcoma AS mortality rates in the UK decreased by 25% between 1979-1981 and 2017-2019.

Over the last decade in the UK (between 2007-2009 and 2017-2019), bone sarcoma AS mortality rates for females and males combined remained stable. In females AS mortality rates remained stable, and in males rates remained stable.

Bone Sarcoma (C40-C41), European Age-Standardised Mortality Rates per 100,000 Persons Population, UK, 1979-2019

For most cancer types, mortality trends largely reflect incidence and survival trends. For example, rising mortality may reflect rising incidence and stable survival, while falling mortality may reflect rising incidence and rising survival.

Bone sarcoma mortality rates have remained stable overall in most broad age groups in females and males combined in the UK since the late 1970s, but have decreased in some.[1-4] Rates in 0-24s have decreased by 42% (though the absolute change is very small as rates are overall low in this age group), in 25-49s have remained stable, in 50-59s have remained stable, in 60-69s have remained stable, in 70-79s have remained stable and in 80+s have remained stable.

Bone Sarcoma (C40-C41), European Age-Standardised Mortality Rates per 100,000 Persons Population, By Age, UK, 1979-2019

References

  1. England and Wales data were accessed from Nomis mortality statistics by underlying cause, sex and age, November 2021: Nomis mortality statistics by underlying cause, sex and age.
  2. Scotland data were provided by ISD Scotland on request, November 2021. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp(link is external).
  3. Northern Ireland data were provided by the Northern Ireland Cancer Registry on request, February 2022. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  4. Population data were published by the Office for National statistics, accessed July 2020. The data can be found here: Population estimates for the UK, England and Wales, Scotland and Northern Ireland, provisional: mid-2019.

About this data

Data is for UK, 1979-2019, C40-C41.

Cancers in children and young people (aged 0-24) are best classified using a different system to cancers in adults, so the figures presented here may not correspond with those elsewhere.

Last reviewed:

For females, bone sarcoma European age standardised (AS) Open a glossary item mortality rates in the UK are projected to rise by 28% between 2023-2025 and 2038-2040, to 1 death per 100,000 per year by 2038-2040.[1].

Male bone cancer mortality data was not suitable for projections due to erratic trends in some age groups.

Bone sarcoma (C40-C41), Observed and Projected Age-Standardised Mortality Rates, by Sex, UK, 1975-2040

Download the data (xlsx)

References

Calculated by the Cancer Intelligence Team at Cancer Research UK, February 2023. Age-period-cohort modelling approach described here, using 2020-based population projections (Office for National Statistics) and observed cancer mortality data (1975-2018).

About this data

Projections are based on mortality data from 1975-2018 (England, Scotland, Wales and Northern Ireland); the above figure presents all UK data from 1975-2018 (observed) and 2019-2040 (projected). Number of deaths and age-standardised rates are presented as annual averages for each 3-year rolling period. ICD-10 codes C40-C41.

Projections are based on observed mortality rates and therefore implicitly include changes in cancer risk factors, diagnosis and treatment. Confidence intervals are not calculated for the projected figures. Projections are by their nature uncertain because unexpected events in future could change the trend. It is not sensible to calculate a boundary of uncertainty around these already uncertain point estimates. Changes are described as 'increase' or 'decrease' if there is any difference between the point estimates.

More on projections methodology

Last reviewed:

There is no evidence for an association between bone sarcoma mortality and deprivation for either males or females in England.[1] England-wide data for 2007-2011 show European age-standardised Open a glossary item mortality rates are similar for both males and females living in the most deprived areas compared with the least deprived.[1]

Bone sarcoma (C40-C41), European Age-Standardised Mortality Rates by Deprivation Quintile, England, 2007-2011

The estimated deprivation gradient in bone sarcoma mortality between people living in the most and least deprived areas in England has not changed in the period 2002-2011.[1

References

  1. Cancer Research UK and National Cancer Intelligence Network. Cancer by deprivation in England: Incidence, 1996-2010, Mortality, 1997-2011. London: NCIN; 2014.

About this data

Data is for: UK, 2007-2011, ICD-10 C40-C41

Deprivation gradient statistics were calculated using mortality data for 2007-2011. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate Online 

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.